FDA Hears 80 Speakers on Psychedelic Drug Therapy Standards
The FDA held a public hearing on psychedelic drug therapy, drawing more than 1,800 registered attendees and 80 speakers...
Ketamine Therapy
LSD Just Beat Phase 3 Twice. Now Comes the Hard Part.
Definium's DT120 cleared Phase 3 in both MDD and GAD. As a ketamine PI who's treated 30,000+ patients, here's...
The Serotonin Signal Hiding in Plain Sight Across Two Rapid-Acting Depression Treatments
A Bayesian PET re-analysis finds ketamine and ECT both upregulate 5-HT1B receptors, pointing to a shared biomarker that TRD...
What a 26-Trial Ketamine Meta-Analysis Gets Right, and What It Still Can’t Capture
A JAMA Psychiatry meta-analysis of 26 RCTs confirms ketamine's acute antidepressant effect. Here's what 1,166 trial patients don't show...
The IT Neuron Finding That Should Reshape How We Design Rapid-Acting Depression Trials
New Cell data pinpoints intratelencephalic neurons in the anterior insula as the mechanistic key to aiTBS antidepressant effects—here's what...
France Just Approved What the U.S. Still Won’t Name: IV Ketamine for Acute Suicidal Crisis
France's March 2026 approval of intravenous racemic ketamine for severe suicidal crisis is the first regulatory action of its...
Oral Brexanolone’s Phase 3 Failure Exposes a Gap Ketamine Already Fills
Lipocine's LPCN 1154 just failed its Phase 3 trial for postpartum depression, sending shares down 77%. For psychiatrists treating...